 |
|
|
| |
Efficacy and Safety of Daclatasvir in Combination With Asunaprevir in Cirrhotic and Non-Cirrhotic Patients With HCV Genotype 1b: Results of the HALLMARK-DUAL Study
|
| |
| |
Reported by Jules Levin
EASL - April 9-13, 2014, The International Liver Congress: The 49th Annual Meeting of the European Association for the Study of the Liver. London, UK,
Kao J-H,1 Heo J,2 Yoffe B,3 Sievert W,4 Jacobson IM,5 Bessone F,6 Peng C-Y,7 Roberts S,8 Yoon KT,9 Kopit J,10 Linaberry M,11 Noviello S,11 Hughes E,11 Manns M12
1National Taiwan University Hospital, Taipei, Taiwan; 2Pusan National University Hospital, Busan, Republic of Korea; 3VAMC, Baylor College of Medicine, Houston, Texas, USA; 4Monash Health and Monash University, Melbourne, Australia; 5Weill Cornell Medical College, New York, New York, USA; 6Instituto CAICI, Rosario, Argentina; 7School of Medicine, China Medical University, Taichung, Taiwan; 8The Alfred Hospital, Melbourne, Australia; 9Pusan National University Yangsan Hospital, Busan, Republic of Korea; 10Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA; 11Bristol-Myers Squibb Research and Development, Princeton, New Jersey, USA; 12Hannover Medical School, Hannover, Germany
|
| |
|
|
|
|
|
